Chapter 28 : Immunogenetics of the Host Response to Viral Infections

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in

Immunogenetics of the Host Response to Viral Infections, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817978/9781555812140_Chap28-1.gif /docserver/preview/fulltext/10.1128/9781555817978/9781555812140_Chap28-2.gif


This chapter reviews the main steps of the adaptive immune responses and discusses the consequences of genetic polymorphism for the susceptibility to viral infections. It also reviews recent important results obtained with particular viral infections of mice and of humans and concludes with some general remarks on the consequences of these studies for both our fundamental understanding of viral pathogenesis and practical applications to human medicine. Extensive polymorphism of class I and class II molecules, the number of alleles, and their heterozygosity account for the ability to mount efficient immune responses against a large variety of infectious agents. Nevertheless, the modulation of the immune response to viruses by the major histocompatibility complex (MHC) haplotype is well documented for mice and other laboratory animals. The genes and their protein products constitute one of the best-characterized systems of genetically regulated control of viral infections. Importantly, the effect of the gene on resistance was not mediated by the adaptive immune responses but was dependent on alpha/beta interferon. A better comprehension of the genetic control of virus infections will help us understand not only how we have evolved but also what we can and cannot achieve with antiviral drugs and vaccines.

Citation: Brahic M, Bureau J, Bangham C, Gachelin G. 2002. Immunogenetics of the Host Response to Viral Infections, p 421-436. In Kaufmann S, Sher A, Ahmed R (ed), Immunology of Infectious Diseases. ASM Press, Washington, DC. doi: 10.1128/9781555817978.ch28
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


Image of Figure 1
Figure 1

Summary of antigen presentation by the MHC class I and class II pathways. The class I pathway, present in all nucleated cells, is illustrated on the right, and the class II pathway, which is specific to antigen-presenting cells, is illustrated on the left. The T cell is at the top, and the presenting cell at the bottom. The asterisks denote the steps in the pathways of antigen processing and presentation in which host polymorphism might influence the specificity or efficiency of immune recognition. Polymorphism in the proteases involved in these pathways (i.e., the proteasomal, cytoplasmic, and endosomal proteases) might affect the repertoire of peptides generated from viral proteins.

Citation: Brahic M, Bureau J, Bangham C, Gachelin G. 2002. Immunogenetics of the Host Response to Viral Infections, p 421-436. In Kaufmann S, Sher A, Ahmed R (ed), Immunology of Infectious Diseases. ASM Press, Washington, DC. doi: 10.1128/9781555817978.ch28
Permissions and Reprints Request Permissions
Download as Powerpoint


1. Allison, A. C. 1964. Polymorphism and natural selection in human populations. Cold Spring Harbor Symp. Quant. Biol. 29: 137 149.
2. Almarri, A.,, and J. Batchelor. 1994. HLA and hepatitis B infection. Lancet 344: 1194 1195.
3. Apple, R. J.,, H. A. Erlich,, W. Klitz,, M. M. Manos,, T. M. Becker,, and C. M. Wheeler. 1994. HLA DR-DQ associations with cervical carcinoma show papillomavirus-type specificity. Nat. Genet. 6: 157 162.
4. Aubagnac, S.,, M. Brahic,, and J.-F. Bureau. 1999. Viral load and a locus on chromosome 11 affect the late clinical disease caused by Theiler’s virus. J. Virol. 73: 7965 7971.
5. Azoulay, A.,, M. Brahic,, and J.-F. Bureau. 1994. FVB mice transgenic for the H-2D b gene become resistant to persistent infection by Theiler’s virus. J. Virol. 68: 4049 4052.
6. Azoulay-Cayla, A.,, S. Dethlefs,, B. Pérarnau,, E. L. Larsson-Sciard,, F. A. Lemonnier,, M. Brahic,, and J.-F. Bureau. 2000. H-2D b-/ - mice are susceptible to persistent infection by Theiler’s virus. J. Virol. 74: 5470 5476.
7. Bangham, C. R.,, S. E. Hall,, K. J. Jeffery,, A. M. Vine,, A. Witkover,, M. A. Nowak,, D. Wodarz,, K. Usuku,, and M. Osame. 1999. Genetic control and dynamics of the cellular immune response to the human T-cell leukaemia virus, HTLV-I. Philos. Trans. R. Soc. London Ser. B 354: 691 700.
8. Bellamy, R.,, C. Ruwende,, T. Corrah,, K. McAdam,, M. Thursz,, H. Whittle,, and A. Hill. 1999. Tuberculosis and chronic hepatitis B virus infection in Africans and variation in the vitamin D receptor gene. J. Infect. Dis. 179: 721 724.
9. Bertoletti, A.,, C. Ferrari,, F. Fiaccadori,, A. Penna,, R. Margolskee,, H. Schlicht,, P. Fowler,, S. Guilhot,, and F. Chisari. 1991. HLA class I restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc. Natl. Acad. Sci. USA 88: 10445 10449.
10. Best, S.,, P. Le Tissier,, G. Towers,, and J. P. Stoye. 1996. Positional cloning of the mouse retrovirus restriction gene Fv1. Nature 382: 826 829.
11. Best, S.,, P. R. Le Tissier,, and J. P. Stoye. 1997. Endogenous retroviruses and the evolution of resistance to retroviral infection. Trends Microbiol. 5: 313 318.
12. Bihl, F.,, M. Brahic,, and J.-F. Bureau. 1999. Two loci, Tmevp2 and Tmevp3, located on the telomeric region of chromosome 10, control the persistence of Theiler’s virus in the central nervous system. Genetics 152: 385 392.
13. Biti, R.,, R. Ffrench,, J. Young,, B. Bennetts,, G. Stewart,, and T. Liang. 1997. HIV-1 infection in an individual homozygous for the CCR5 deletion allele. Nat. Med. 3: 252 253.
14. Bjorkman, P. J.,, M. A. Saper,, B. Samraoui,, W. S. Bennett,, J. L. Strominger,, and D. C. Wiley. 1987. Structure of the human class I histocompatibility antigen HLA-A2. Nature 329: 506.
15. Bonneville, M.,, and J. J. Fournié. 1999. γδ T lymphocytes, a link between immunity and homeostasis? Microbes Infect. 1: 173.
16. Bontkes, H. J.,, M. van Duin,, T. D. de Gruijl,, M. F. Duggan-Keen,, J. M. Walboomers,, M. J. Stukart,, R. H. Verheijen,, T. J. Helmerhorst,, C. J. Meijer,, R. J. Scheper,, F. R. Stevens,, P. A. Dyer,, P. Sinnott,, and P. L. Stern. 1998. HPV 16 infection and progression of cervical intra-epithelial neoplasia: analysis of HLA polymorphism and HPV 16 E6 sequence variants. Int. J. Cancer 78: 166 171.
17. Brahic, M.,, and J.-F. Bureau. 1998. Genetics of susceptibility to Theiler’s virus infection. Bioessays 20: 627 633.
18. Brinton, M. A. 1983. Analysis of extracellular West Nile virus particles produced by cell cultures from genetically resistant and susceptible mice indicates enhanced amplification of defective interfering particles by resistant cultures. J. Virol. 46: 860 870.
19. Bureau, J.-F.,, K. M. Drescher,, L. R. Pease,, T. Vikoren,, M. Delcroix,, L. Zoecklein,, M. Brahic,, and M. Rodriguez. 1998. Chromosome 14 contains determinants that regulate susceptibility to Theiler’s virus-induced demyelination in the mouse. Genetics 148: 1941 1949.
20. Bureau, J.-F.,, X. Montagutelli,, F. Bihl,, S. Lefebvre,, J.-L. Guénet,, and M. Brahic. 1993. Mapping loci influencing the persistence of Theiler’s virus in the murine central nervous system. Nat. Genet. 5: 87 91.
21. Bureau, J.-F.,, X. Montagutelli,, S. Lefebvre,, J.-L. Guénet,, M. Pla,, and M. Brahic. 1992. The interaction of two groups of murine genes determines the persistence of Theiler’s virus in the central nervous system. J. Virol. 66: 4698 4704.
22. Burrows, J.,, S. Burrows,, L. Poulsen,, T. Sculley,, D. Moss,, and R. Khanna. 1996. Unusually high frequency of Epstein-Barr virus genetic variants in Papua New Guinea that can escape cytotoxic T-cell recognition: implications for virus evolution. J. Virol. 70: 2490 2496.
23. Carrington, M.,, G. W. Nelson,, M. P. Martin,, T. Kissner,, D. Vlahov,, J. J. Goedert,, R. Kaslow,, S. Buchbinder,, K. Hoots,, and S. J. O’Brien. 1999. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 283: 1748 1752.
24. Cesarman, E.,, A. Chadburn,, Y. Liu,, A. Migliazza,, R. Dalla- Favera,, and D. Knowles. 1998. BCL-6 gene mutations in post-transplantation lymphoproliferative disorders predict response to therapy and clinical outcome. Blood 92: 2294 2302.
25. Chesebro, B.,, M. Miyazawa,, and W. J. Britt. 1990. Host genetic control of spontaneous and induced immunity to friend murine retrovirus infection. Annu. Rev. Immunol. 8: 477 499.
26. Chisari, F., and C. Ferrari. 1995. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 13: 29 60.
27. Clatch, R. J.,, R. W. Melvold,, S. D. Miller,, and H. L. Lipton. 1985. Theiler’s murine encephalomyelitis virus (TMEV) induced demyelinating disease in mice is influenced by the H-2D region: correlation with TMEV specific delayed-type hypersensitivity. J. Immunol. 135: 1408 1413.
28. Cresswell, P. 1994. Assembly, transport, and function of MHC class II molecules. Annu. Rev. Immunol. 12: 259 293.
29. de Campos-Lima, P.-O.,, R. Gavioli,, Q.-J. Zhang,, L. Wallace,, R. Dolcetti,, M. Rowe,, A. Rickinson,, and M. Masucci. 1993. HLAA11 epitope loss isolates of Epstein-Barr virus from a highly A11+ population. Science 260: 98 100.
30. Dethlefs, S.,, M. Brahic,, and E. L. Larsson-Sciard. 1997. An early, abundant cytotoxic T-lymphocyte response against Theiler’s virus is critical for preventing viral persistence. J. Virol. 71: 8875 8878.
31. Edwards-Smith, C.,, J. Jonsson,, D. Purdie,, A. Bansal,, C. Shorthouse,, and E. Powell. 1999. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 30: 526 530.
32. Evans, D. T.,, D. H. O’Connor,, P. Jing,, J. L. Dzuris,, J. Sidney,, J. da Silva,, T. M. Allen,, H. Horton,, J. E. Venham,, R. A. Rudersdorf,, T. Vogel,, C. D. Pauza,, R. E. Bontrop,, R. DeMars,, A. Sette,, A. L. Hughes,, and D. I. Watkins. 1999. Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef. Nat. Med. 5: 1270 1276.
33. Ferrari, A. C.,, H. N. Seuanez,, S. M. Hanash,, and G. F. Atweh. 1990. A gene that encodes for a leukemia-associated phosphoprotein (p18) maps to chromosome bands 1p35-36.1. Genes, Chromosomes Cancer 2: 125 129.
34. Fiette, L.,, C. Aubert,, U. Müller,, S. Huang,, M. Aguet,, M. Brahic,, and J.-F. Bureau. 1995. Theiler’s virus infection of 129Sv mice that lack the interferon α /β or interferon γ receptors. J. Exp. Med. 181: 2069 2076.
35. Flanders, W. D.,, and M. J. Khoury. 1996. Analysis of case parental control studies: method for the study of associations between disease and genetic markers. Am. J. Epidemiol. 144: 696 703.
36. Gardner, M. B.,, C. A. Kozak,, and S. J. O’Brien. 1991. The Lake Casitas wild mouse: evolving genetic resistance to retroviral disease. Trends Genet. 7: 22 27.
37. Giani, G.,, M. Chiaramonte,, C. Pasini,, U. Fagiolo,, and R. Naccarato. 1979. Hepatitis B surface antigenaemia and HLA antigens. N. Engl. J. Med. 300: 1056.
38. Goulder, P.,, R. Phillips,, R. Colbert,, S. McAdam,, G. Ogg,, M. Nowak,, P. Giangrande,, G. Luzzi,, B. Morgan,, A. Edwards,, A. McMichael,, and S. Rowland-Jones. 1997. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat. Med. 3: 212 217.
39. Groschel, D.,, and H. Koprowski. 1965. Development of a virus-resistant inbred mouse strain for the study of innate resistance to Arbo B viruses. Arch. Gesamte Virusforsch 17: 379 391.
40. Haldane, J. B. S. 1949. Disease and evolution. Ric. Sci. 19(Suppl.): 68 76.
41. Haller, O.,, M. Acklin,, and P. Staeheli. 1987. Influenza virus resistance of wild mice: wild-type and mutant Mx alleles occur at comparable frequencies. J. Interferon Res. 7: 647 656.
42. Haller, O.,, M. Frese,, and G. Kochs. 1998. Mx proteins: mediators of innate resistance to RNA viruses. Rev. Sci. Tech. Off. Int. Epizool. 17: 220 230.
43. Haller, O.,, M. Frese,, D. Rost,, P. A. Nutall,, and G. Kochs. 1995. Tick-borne Thogoto virus infection in mice is inhibited by orthomyxovirus resistance gene product. J. Virol. 69: 2596 2601.
44. Hamilton, W. D.,, R. Axelrod,, and R. Tanese. 1990. Sexual reproduction as an adaptation to resist parasites. Proc. Natl. Acad. Sci. USA 87: 3566 3573.
45. Hasenkrug, K. J.,, and B. Chesebro. 1997. Immunity to retroviral infection: the friend virus model. Proc. Natl. Acad. Sci. USA 94: 7811 7816.
46. Hayney, M.,, G. Poland,, P. Dimanlig,, D. Schaid,, R. Jacobson,, and J. Lipsky. 1997. Polymorphisms of the TAP2 gene may influence antibody response to live measles vaccine virus. Vaccine 15: 3 6.
47. Hayney, M.,, G. Poland,, R. Jacobson,, D. Schaid,, and J. Lipsky. 1996. The influence of the HLA-DRB1*13 allele on measles vaccine response. J. Investig. Med. 44: 261 263.
48. Hill, A. V.,, C. E. Allsopp,, D. Kwiatkowski,, N. M. Anstey,, P. Twumasi,, P. A. Rowe,, S. Bennett,, D. Brewster,, A. J. Mc- Michael,, and B. M. Greenwood. 1991. Common west African HLA antigens are associated with protection from severe malaria. Nature 352: 595 600.
49. Hill, A. V. S. 1998. The immunogenetics of human infectious diseases. Annu. Rev. Immunol. 16: 593 617.
50. Hohler, T.,, G. Gerken,, A. Notghi,, R. Lubjuhn,, H. Taheri,, U. Protzer,, H. Lohr,, P. Schneider,, K. Meyer zum Buschenfelde,, and C. Rittner. 1997. HLA-DRBl*l301 and *1302 protect against chronic hepatitis B. J. Hepatol. 26: 503 507.
51. Hughes, A. L.,, and M. K. Hughes. 1995. Natural selection on the peptide-binding regions of major histocompatibility complex molecules. Immunogenetics 42: 233 243.
52. Ikeda, H.,, and H. Sugimura. 1989. Fv-4 resistance gene: a truncated endogenous murine leukemia virus with ecotropic interference properties. J. Virol. 63: 5405 5412.
53. Itescu, S.,, U. Mathur Wagh,, M. L. Skovron,, L. J. Brancato,, M. Marmor,, J. A. Zeleniuch,, and R. Winchester. 1992. HLA-B35 is associated with accelerated progression to AIDS. J. Acquired Immune Defic. Syndr. 5: 37 45.
54. Jacobson, S.,, H. Shida,, D. McFarlin,, A. Fauci,, and S. Koenig. 1990. Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature 348: 245 248.
55. Jeannet, M.,, R. Sztajzel,, N. Carpentier,, B. Hirschel,, and J. M. Tiercy. 1989. HLA antigens are risk factors for development of AIDS. J. Acquired Immune Defic. Syndr. 2: 28 32.
56. Jeffery, K.,, K. Usuku,, S. Hall,, W. Matsumoto,, G. Taylor,, J. Procter,, M. Bunce,, G. Ogg,, K. Welsh,, J. Weber,, A. Lloyd,, M. Nowak,, M. Nagai,, D. Kodama,, S. Izumo,, M. Osame,, and C. Bangham. 1999. HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-Iassociated myelopathy. Proc. Natl. Acad. Sci. USA 96: 3848 3853.
57. Jeffery, K.,, A. A. Siddiqui,, M. Bunce,, A. L. Lloyd,, A. M. Vine,, A. D. Witkoven,, S. Izumo,, K. Usuku,, K. I. Welsh,, M. Osame,, and C. R. Bangham. 2000. The influence of HLA class I alleles and heterozygosity on the outcome of human T cell lymphotropic virus type I infection. J. Immunol. 12: 7278 7284.
58. Jin, H. K.,, T. Yamashita,, K. Ochiai,, O. Haller,, and T. Watanabe. 1998. Characterization and expression of the Mx1 gene in wild mouse species. Biochem. Genet. 36: 311 322.
59. Jolicoeur, P. 1979. The Fv-1 gene of the mouse and its control of murine leukemia virus replication. Curr. Top. Microbiol. Immunol. 86: 67 122.
60. Kalams, S.,, S. Buchbinder,, E. Rosenberg,, J. Billingsley,, D. Colbert,, N. Jones,, A. Shea,, A. Trocha,, and B. Walker. 1999. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. J. Virol. 73: 6715 6720.
61. Kannagi, M.,, S. Harada,, I. Maruyama,, H. Inoko,, H. Igarashi,, G. Kumashima,, S. Sato,, and M. Morita. 1991. Predominant recognition of human T cell leukemia virus type I (HTLV-I) pX gene products by human CD8+ cytotoxic T cells directed against HTLV-I-infected cells. Int. Immunol. 3: 761 767.
62. Kaslow, R. A.,, M. Carrington,, R. Apple,, L. Park,, A. Munoz,, A. J. Saah,, J. J. Goedert,, C. Winkler,, S. J. O’Brien,, C. Rinaldo,, R. Detels,, W. Blattner,, J. Phair,, H. Erlich,, and D. L. Mann. 1996. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat. Med. 2: 405 411.
63. Kaslow, R. A.,, R. Duquesnoy,, M. VanRaden,, L. Kingsley,, M. Marrari,, H. Friedman,, S. Su,, A. J. Saah,, R. Detels,, J. Phair,, and C. Rinaldo. 1990. Al, Cw7, B8, DR3 HLA antigen combination associated with rapid decline of T helper lymphocytes in HIV-I infection. Lancet 335: 927 930.
64. Kiviat, N.,, A. Rompalo,, R. Bowden,, D. Galloway,, K. K. Holmes,, L. Corey,, P. L. Roberts,, and W. E. Stamm. 1990. Anal human papillomavirus infection among human immunodeficiency virus-seropositive and -seronegative men. J. Infect. Dis. 162: 358 361.
65. Klein, M. R.,, I. P. Keet,, J. D’Amaro,, R. J. Bende,, A. Hekman,, B. Mesman,, M. Koot,, L. P. de Waal,, R. A. Coutinho,, and F. Miedema. 1994. Associations between HLA frequencies and pathogenic features of human immunodeficiency virus type I infection in seroconverters from the Amsterdam cohort of homosexual men. J. Infect. Dis. 169: 1244 1259.
66. Kochs, G.,, and O. Haller. 1999a. GTP-bound human MxA protein interacts with the nucleocapsids of Thogoto virus (Orthomyxoviridae). J. Biol. Chem. 274: 4370 4376.
67. Kochs, G.,, and O. Haller. 1999b. Interferon-induced human MxA GTPase blocks nuclear import of Thogoto virus nucleocapsids. Proc. Natl. Acad. Sci. USA 96: 2082 2086.
68. Kozak, C. A. 1985. Analysis of wild-derived mice for Fv-1 and Fv-2 murine leukemia virus restriction loci: a novel wild mouse Fv-1 allele responsible for lack of host range restriction. J. Virol. 55: 281 285.
69. Kuzushita, N.,, N. Hayashi,, T. Moribe,, K. Katayama,, T. Kanto,, S. Nakatani,, T. Kaneshige,, T. Tatsumi,, A. Ito,, K. Mochizuki,, Y. Sasaki,, A. Kasahara,, and M. Hori. 1998. Influence of HLA haplotypes on the clinical courses of individuals infected with hepatitis C virus. Hepatology 27: 240 244.
70. Libert, F.,, P. Cochaux,, G. Beckman,, M. Samson,, M. Aksenova,, A. Cao,, A. Czeizel,, M. Claustres,, C. de la Rua,, M. Ferrari,, C. Ferrec,, G. Glover,, B. Grinde,, S. Güran,, V. Kucinskas,, J. Lavinha,, B. Mercier,, G. Ogur,, L. Peltonen,, C. Rosatelli,, M. Schwartz,, V. Spitsyn,, L. Timar,, L. Beckman,, M. Parmentier,, and G. Vassart. 1998. The deltaccr5 mutation conferring protection against HIV-1 in Caucasian populations has a single and recent origin in Northeastern Europe. Hum. Mol. Genet. 7: 399 406.
71. Lin, T.,, C. Chen,, M. Wu,, C. Yang,, J. Chen,, C. Lin,, T. Kwang,, S. Hsu,, S. Lin,, and L. Hsu. 1989. Hepatitis B virus markers in Chinese twins. Anticancer Res. 9: 737 741.
72. Lindenmann, J. 1962. Resistance of mice to mouse adapted influenza A virus. Virology 16: 203 204.
73. Lipton, H. L.,, R. Melvold,, S. D. Miller,, and M. C. Dal Canto. 1995. Mutation of a major histocompatibility class I locus, H- 2D, leads to an increased virus burden and disease susceptibility in Theiler’s virus-induced demyelinating disease. J. Neurovirol. 1: 138 144.
74. Liu, R.,, W. Paxton,, S. Choe,, D. Ceradini,, S. Martin,, R. Horuk,, M. MacDonald,, H. Stuhlmann,, R. Koup,, and N. Landau. 1996. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HlV-1 infection. Cell 86: 367 377.
75. Louagie, H.,, J. Brouwer,, J. Delanghe,, M. De Buyzere,, and G. Leroux-Roels. 1996. Haptoglobin polymorphism and chronic hepatitis C. J. Hepatol. 25: 10 14.
76. Magierowska, M.,, I. Theodorou,, P. Debre,, F. Sanson,, B. Autran,, Y. Riviere,, D. Charron,, and D. Costagliola. 1999. Combined genotypes of CCR5, CCR2, SDF1, and HLA genes can predict the long-term nonprogressor status in human immunodeficiency virus-1-infected individuals. Blood 93: 936 941.
77. Martin, M.,, M. Dean,, M. Smith,, C. Winkler,, B. Gerrard,, N. Michael,, B. Lee,, R. Dams,, J. Margolick,, S. Buchbinder,, J. J. Goedert,, T. R. O’Brien,, M. W. Hilgartner,, D. Vlahov,, S. J. O’Brien,, and M. Carrington. 1998. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 282: 1907 1911.
78. McDermott, D.,, P. Zimmerman,, F. Guignard,, C. Kleeberger,, S. Leitman,, and P. Murphy. 1998. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet 352: 866 870.
79. McGlynn, K.,, E. Rosvold,, E. Lustbader,, Y. Hu,, M. Clapper,, T. Zhou,, C. Wild,, X. Xia,, A. Baffoe Bonnie,, D. Ofori Adjei,, G. C. Chen,, W. T. London,, F. M. Shen,, and K. H. Buetow. 1995. Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. Proc. Natl. Acad. Sci. USA 92: 2384 2387.
80. McMichael, A.,, and R. Phillips. 1997. Escape of human immunodeficiency virus from immune control. Annu. Rev. Immunol. 15: 271 296.
81. McNeil, A. J.,, P. L. Yap,, S. M. Gore,, R. P. Brettle,, M. McColl,, R. Wyld,, S. Davidson,, R. Weightman,, A. M. Richardson,, and J. R. Robertson. 1996. Association of HLA types A1 B8 DR3 and B27 with rapid and slow progression of HIV disease. Q. J. Med. 89: 177 185.
82. Mead, R.,, D. Jack,, M. Pembrey,, L. Tyfield,, and M. Turner. 1997. Mannose binding lectin alleles in a prospectively recruited UK population. Lancet 349: 1669 1670.
83. Michael, N. 1999. Host genetic influences on HIV-1 pathogenesis. Curr. Opin. Immunol. 11: 466 474.
84. Monteyne, P.,, F. Bihl,, F. Levillayer,, M. Brahic,, and J.-F. Bureau. 1999. The Th1/Th2 balance does not account for the difference of susceptibility of mouse strains to Theiler’s virus persistent infection. J. Immunol. 162: 7330 7334.
85. Monteyne, P.,, J.-F. Bureau,, and M. Brahic. 1997. The infection of mouse by Theiler’s virus: from genetics to immunology. Immunol. Rev. 159: 163 176.
86. Moreau-Gachelin, F.,, A. Tavitian,, and P. Tambourin. 1988. Spi-1 is a putative oncogene in virally induced murine erythroleukaemias. Nature 331: 277 280.
87. Mota, A.,, R. Fainboim,, R. Terg,, and L. Fainboim. 1987. Association of chronic active hepatitis and HLA-B35 in patients with hepatitis B virus. Tissue Antigen 30: 238 240.
88. Müller, U.,, U. Steinhoff,, L. F. L. Reis,, S. Hemmi,, J. Pavlovic,, R. M. Zinkernagel,, and M. Aguet. 1994. Functional role of type I and type II interferons in antiviral defense. Science 264: 1918 1921.
89. Mummidi, S.,, S. Ahuja,, E. Gonzalez,, S. Anderson,, E. Santiago,, K. Stephan,, F. Craig,, P. O’Connell,, V. Tryon,, R. A. Clark,, M. J. Dolan,, and S. Ahuja. 1998. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HlV-1 disease progression. Nat. Med. 4: 786 793.
90. Nagai, M.,, K. Usuku,, W. Matsumoto,, D. Kodama,, N. Takenouchi,, T. Moritoyo,, S. Hashiguchi,, M. Ichinose,, C. R. M. Bangham,, S. Izumo,, and M. Osame. 1998. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J. Neurovirol. 4: 586 593.
91. Niewiesk, S.,, S. Daenke,, C. E. Parker,, G. Taylor,, J. Weber,, S. Nightingale,, and C. R. Bangham. 1994. The transactivator gene of human T-cell leukemia virus type I is more variable within and between healthy carriers than patients with tropical spastic paraparesis. J. Virol. 68: 6778 6781.
92. Ohta, T. 1999. Effect of gene conversion on polymorphic patterns at major histocompatibility complex loci. Immunol. Rev. 167: 319 325.
93. Ojcius, D. M.,, C. Delarbre,, P. Kourilsky,, and G. Gachelin. 1994. Major histocompatibility complex class I molecules and resistance against intracellular pathogens. Crit. Rev. Immunol. 14: 193 220.
94. Parker, C.,, S. Daenke,, S. Nightingale,, and C. Bangham. 1992. Activated HTLV-I specific cytotoxic T cells are found in healthy seropositives as well as patients with tropical spastic paraparesis. Virology 188: 628 636.
95. Paul, R.,, S. Schuetze,, S. L. Kozak,, C. A. Kozak,, and D. Kabat. 1991. The Sfpi-1 proviral integration site of Friend erythroleukemia encodes the ets-related transcription factor Pu.1. J. Virol. 65: 464 467.
96. Persons, D. A.,, R. F. Paulson,, M. R. Loyd,, M. T. Herley,, S. M. Bodner,, A. Bernstein,, P. H. Correll,, and P. A. Ney. 1999. Fv2 encodes a truncated form of the Stk receptor tyrosine kinase. Nat. Genet. 23: 159 165.
97. Phillips, R. E.,, S. Rowland-Jones,, D. F. Nixon,, F. M. Gotch,, J. P. Edwards,, A. O. Ogunlesi,, J. G. Elvin,, J. A. Rothbard,, C. R. Bangham,, C. R. Rizza,, and A. J. McMichael. 1991. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 354: 453 459.
98. Piyasirisilp, S.,, B. Schmeckpeper,, D. Chandanayingyong,, T. Hemachudha,, and D. Griffin. 1999. Association of HLA and T-cell receptor gene polymorphisms with Semple rabies vaccine-induced autoimmune encephalomyelitis. Ann. Neurol. 45: 595 600.
99. Porcelli, S. A.,, and R. L. Modlin. 1999. The CD1 system: antigen-presenting molecules for T cell recognition of lipids and glycolipids. Annu. Rev. Immunol. 17: 297 329.
100. Price, D. A.,, P. J. Goulder,, P. Klenerman,, A. K. Sewell,, P. J. Easterbrook,, M. Troop,, C. R. Bangham,, and R. E. Phillips. 1997. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc. Natl. Acad. Sci. USA 94: 1890 1895.
101. Rammensee, H. G.,, T. Friede,, and S. Stevanoviic. 1995. MHC ligands and peptide motifs: first listing. Immunogenetics 41: 178 228.
102. Ramoz, N.,, L. A. Rueda,, B. Bouadjar,, M. Favre,, and G. Orth. 1999. A susceptibility locus for epidermodysplasia verruciformis, an abnormal predisposition to infection with the oncogenic human papillomavirus type 5, maps to chromosome 17qter in a region containing a psoriasis locus. J. Investig. Dermatol. 112: 259 263.
103. Ramoz, N.,, A. Taieb,, L. A. Rueda,, L. S. Montoya,, B. Bouadjar,, M. Favre,, and G. Orth. 2000. Evidence for a non-allelic heterogeneity of epidermodysplasia verruciformis with two susceptibility loci mapped to chromosome regions 2p21-p24 and 17q25. J. Investig. Dermatol. 114: 1148 1153.
104. Reeves, R. H.,, B. F. O’Hara,, W. J. Pavan,, J. D. Gearhart,, and O. Haller. 1988. Genetic mapping of the Mx influenza virus-resistance gene within the region of mouse chromosome 16 that is homologous to human chromosome 21. J. Virol. 62: 4372 4375.
105. Risch, N. 1990. Linkage strategies for genetically complex traits. II. The power of affected relative pairs. Am. J. Hum. Genet. 46: 229 241.
106. Rock, K. L.,, and A. L. Goldberg. 1999. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu. Rev. Immunol. 17: 739 779.
107. Rodriguez, M.,, and C. S. David. 1995. H-2D d transgene suppresses Theiler’s virus-induced demyelination in susceptible strains of mice. J. Neurovirol. 1: 111 117.
108. Rodriguez, M.,, J. L. Leibowitz,, and C. S. David. 1986. Susceptibility to Theiler’s virus-induced demyelination. Mapping of the gene within the H-2D region. J. Exp. Med. 163: 620 631.
109. Rowland-Jones, S.,, J. Sutton,, K. Ariyoshi,, T. Dong,, F. Gotch,, S. McAdam,, D. Whitby,, S. Sabally,, A. Gallimore,, T. Corrah,, M. Takiguchi,, T. Schultz,, A. McMichael,, and H. Whittle. 1995. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat. Med. 1: 59 64.
110. Sabin, A.B. 1952. Genetic, hormonal and age factors in natural resistance to certain viruses. Ann. N. Y. Acad. Sci. 54: 936 944.
111. Sahmoud, T.,, Y. Laurian,, C. Gazengel,, Y. Sultan,, C. Gautreau,, and D. Costagliola. 1993. Progression to AIDS in French haemophiliacs: association with HLA B35. AIDS 7: 497 500.
112. Sampson, M.,, F. Libert,, B. Doranz,, J. Rucker,, C. Liesnard,, C.-M. Farber,, S. Saragosti,, C. Lapoumeroulie,, J. Cognaux,, C. Forceille, et al. 1996. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382: 722 725.
113. Sangster, M. Y.,, N. Urosevic,, J. P. Mansfield,, J. S. Mackenzie,, and G. R. Shellam. 1994. Mapping the Flv locus controlling resistance to flaviviruses on mouse chromosome 5. J. Virol. 68: 448 452.
114. Sawyer, W.,, K. Meyer,, M. Eaton,, J. Bauer,, P. Putnam,, and F. Schwentker. 1944. Jaundice in army personnel in the western region of the United States and its relation to vaccination against yellow fever. Am. J. Hyg. 39: 337 440.
115. Scorza-Smeraldi, R.,, G. Fabio,, A. Lazzarin,, N. B. Eisera,, M. Moroni,, and C. Zanussi. 1986. HLA associated susceptibility to acquired immunodeficiency syndrome in Italian patients with human immunodeficiency virus infection. Lancet ii: 1187 1189.
116. Shellam, G. R.,, M. Y. Sangster,, and N. Urosevic. 1998. Genetic control of host resistance to flavivirus infection in animals. Rev. Sci. Tech. 17: 231 248.
117. Shi, P. Y.,, W. Li,, and M. A. Brinton. 1996. Cell proteins bind specifically to West Nile virus minus-strand 3’ stem-loop RNA. J. Virol. 70: 6278 6287.
118. Smith, M.,, M. Dean,, M. Carrington,, C. Winkler,, G. Huttley,, D. Lomb,, J. Goedert,, T. O’Brien,, L. Jacobsen,, R. Kaslow,, S. Buchbinder,, E. Vittinghoff,, D. Vlahov,, K. Hoots,, M. W. Hilgartner,, and S. J. O’Brien. 1997. Contrasting genetic influence of CCR2 and CCR5 variants on HlV-1 infection and disease progression. Haemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort, ALIVE Study. Science 277: 959 965.
119. Staeheli, P.,, R. Grob,, E. Meier,, J. G. Sucliffe,, and O. Haller. 1988. Influenza virus-susceptible mice carry Mx genes with a large deletion or a nonsense mutation. Mol. Cell. Biol. 8: 4518 4523.
120. Staeheli, P.,, and O. Haller. 1985. Interferon-induced human protein with homology to protein Mx of influenza virus resistant mice. Mol. Cell. Biol. 5: 2150 2153.
121. Staeheli, P.,, and J. G. Sutcliffe. 1988. Identification of a second interferon-regulated murine Mx gene. Mol. Cell. Biol. 8: 4524 4528.
122. Stephens, J.,, D. Reich,, D. Goldstein,, H. Shin,, M. Smith,, M. Carrington,, C. Winkler,, G. Huttley,, R. Allikmets,, L. Schriml,, B. Gerrard,, M. Malasky,, M. D. Ramos,, S. Morlot,, M. Tzetis,, C. Oddoux,, F. S. di Giovine,, G. Nasioulas,, D. Chandler,, M. Aseev,, M. Hanson,, L. Kalaydjieva,, D. Glavac,, P. Gasparini,, D. Kanavakis,, M. Claustres,, M. Kambouris,, H. Ostrer,, G. Duff,, V. Baranov,, H. Sibul,, A. Metspalu,, D. Goldman,, N. Martin,, D. Duffy,, J. Schmidtke,, X. Estivill,, S. J. O’Brien,, and M. Dean. 1998. Dating the origin of the CCR5-A32 AIDS-resistance allele by the coalescence of haplotypes. Am. J. Hum. Genet. 62: 1507 1515.
123. Stoye, J. P. 1998. Fv1, the mouse retrovirus resistance gene. Rev. Sci. Tech. 17: 269 277.
124. Summerfield, J.,, M. Sumiya,, M. Levin,, and M. Turner. 1997. Association of mutations in mannose binding protein gene with childhood infection in consecutive hospital series. Br. Med. J. 314: 1229 1232.
125. Super, H. J.,, K. J. Hasenkrug,, S. Simmons,, D. M. Brooks,, R. Konzek,, K. D. Sarge,, R. I. Morimoto,, N. A. Jenkins,, D. J. Gilbert,, N. G. Copeland,, W. Frankel,, and B. Chesebro. 1999. Fine mapping of the friend retrovirus resistance gene, Rfv3, on mouse chromosome 15. J. Virol. 73: 7848 7852.
126. Thomas, H.,, G. Foster,, M. Sumiya,, D. Mcintosh,, D. Jack,, M. Turner,, and M. Summerfield. 1996. Mutation of gene of mannose binding protein associated with chronic hepatitis B viral infection. Lancet 348: 1417 1419.
127. Thursz, M.,, D. Kwiatkowski,, C. Allsopp,, B. Greenwood,, H. Thomas,, and A. Hill. 1995. Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N. Engl. J. Med. 332: 1065 1069.
128. Thursz, M.,, H. Thomas,, B. Greenwood,, and A. Hill. 1997. Heterozygote advantage for HLA class II type in hepatitis B virus infection. Nat. Genet. 17: 11 12.
129. Townsend, A. R. M.,, J. Rothbard,, F. M. Gotch,, G. Bahadur,, D. Wraith,, and J. McMichael. 1986. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 44: 959 968.
130. Urosevic, N.,, M. van Maanen,, J. P. Mansfield,, J. S. Mackenzie,, and G. R. Shellam. 1997. Molecular characterization of virus-specific RNA produced in the brains of flavivirus-susceptible and -resistant mice after challenge with Murray Valley encephalitis virus. J. Gen. Virol. 78: 23 29.
131. Usuku, K.,, M. Nishizawa,, K. Matsuki,, K. Tokunaga,, K. Takahashi,, N. Eiraku,, M. Suehara,, T. Juji,, M. Osame,, and T. Tabira. 1990. Association of a particular amino acid sequence of the HLA-DR beta1 chain with HTLV-I-associated myelopathy. Eur. J. Immunol. 20: 1603 1606.
132. Usuku, K.,, S. Sonoda,, M. Osame,, S. Yashiki,, K. Takahashi,, T. Sawada,, M. Matsumoto,, M. Tara,, K. Tsuji,, and A. Igata. 1988. HLA haplotype-linked high immune responsiveness against HTLV-I in HTLV-I-associated myelopathy: comparison with adult T-cell leukemia /lymphoma. Ann. Neurol. 23(Suppl.): S143 S150.
133. van Rij, R.,, S. Broersen,, J. Goudsmit,, R. Coutinho,, and H. Scuitemaker. 1998. The role of a stromal cell-derived factor-1 chemokine gene variant in the clinical course of HIV-1 infection. AIDS 12: F85 F90.
134. Vermund, S.,, K. Kelley,, R. Klein,, A. R. Feingold,, K. Schreiber,, G. Munk,, and R. D. Burk. 1991. High risk of human papillomavirus infection and cervical squamous intraepithelial lesions among women with symptomatic human immunodeficiency virus infection. Am. J. Obstet. Gynecol. 165: 392 400.
135. Vogel, T. U.,, D. T. Evans,, J. A. Urvater,, D. H. O’Connor,, A. L. Hughes,, and D. I. Watkins. 1999. Major histocompatibility complex class I genes in primates: co-evolution with pathogens. Immunol. Rev. 167: 327 337.
136. Weiss, R.,, N. Teich,, H. Varmus,, and J. Coffin (ed.). 1982. RNA Tumor Viruses, p. 871 874. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
137. Winkler, C.,, W. Modi,, M. Smith,, G. Nelson,, X. Wu,, M. Carrington,, M. Dean,, T. Honjo,, K. Tashiro,, D. Yabe,, S. Buchbinder,, E. Vittinghoff,, J. J. Goedert,, T. R. O’Brien,, L. P. Jacobson,, R. Detels,, S. Donfield,, A. Willoughby,, E. Gomperts,, D. Vlahov,, J. Phair,, and S. J. O’Brien. 1998. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science 279: 389 393.
138. Zinkernagel, R. M.,, and P. C. Doherty. 1974. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 248: 701 702.

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error